Skip to Content

Equetro Side Effects

Generic Name: carbamazepine

Note: This page contains information about the side effects of carbamazepine. Some of the dosage forms included on this document may not apply to the brand name Equetro.

In Summary

Common side effects of Equetro include: ataxia, dizziness, drowsiness, nausea, and vomiting. Other side effects include: pruritus, speech disturbance, amblyopia, and xerostomia. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to carbamazepine: oral capsule extended release, oral suspension, oral tablet, oral tablet chewable, oral tablet extended release

Other dosage forms:

In addition to its needed effects, some unwanted effects may be caused by carbamazepine (the active ingredient contained in Equetro). In the event that any of these side effects do occur, they may require medical attention.

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking carbamazepine:

More common:
  • Blurred vision or double vision
  • continuous back-and-forth eye movements
Less common:
  • Actions that are out of control
  • behavioral changes (especially in children)
  • confusion, agitation, or hostility (especially in the elderly)
  • diarrhea (severe)
  • discouragement
  • drooling
  • fear
  • feeling of unreality
  • feeling sad or empty
  • headache (continuing)
  • increase in seizures
  • irritability
  • lack of appetite
  • loss of balance control
  • loss of interest or pleasure
  • muscle trembling, jerking, or stiffness
  • nausea and vomiting (severe)
  • other problems with muscle control or coordination
  • sense of detachment from self or body
  • shakiness and unsteady walk
  • shuffling walk
  • stiffness of the limb
  • sudden, wide mood swings
  • talking, feeling, and acting with excitement
  • thoughts or attempts of killing oneself
  • tiredness
  • trouble concentrating
  • trouble sleeping
  • twisting movements of the body
  • uncontrolled movements, especially of the face, neck, and back
  • unusual drowsiness
  • Black, tarry stools
  • blood in the urine or stools
  • bone or joint pain
  • chest pain
  • cough or hoarseness
  • darkening of the urine
  • difficulty with speaking or slurred speech
  • fainting
  • frequent urination
  • irregular, pounding, or unusually slow heartbeat
  • lower back or side pain
  • mental depression with restlessness and nervousness or other mood or mental changes
  • muscle or stomach cramps
  • nosebleeds or other unusual bleeding or bruising
  • numbness, tingling, pain, or weakness in the hands and feet
  • pain, tenderness, swelling, or bluish color in the leg or foot
  • painful or difficult urination
  • pale stools
  • pinpoint red spots on the skin
  • rapid weight gain
  • rigidity
  • ringing, buzzing, or other unexplained sounds in the ears
  • skin rash, hives, or itching
  • sore throat, chills, and fever
  • sores, ulcers, or white spots on the lips or in the mouth
  • swelling of the face, hands, feet, or lower legs
  • swollen or painful glands
  • sudden decrease in the amount of urine
  • tightness in the chest
  • trembling
  • troubled breathing
  • uncontrolled body movements
  • unusual tiredness or weakness
  • visual hallucinations (seeing things that are not there)
  • yellow eyes or skin

Minor Side Effects

Some of the side effects that can occur with carbamazepine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:
  • Dizziness (mild)
  • drowsiness (mild)
  • lightheadedness
  • nausea or vomiting (mild)
Less common or rare:
  • Accidental injury
  • aching joints or muscles
  • acid or sour stomach
  • back pain
  • belching
  • constipation
  • diarrhea
  • dryness of the mouth
  • headache
  • heartburn
  • increased sensitivity of the skin to sunlight (skin rash, itching, redness or other discoloration of the skin, or severe sunburn)
  • increased sweating
  • indigestion
  • irritation or soreness of the tongue or mouth
  • lack or loss of strength
  • loss of hair
  • loss of memory
  • problems with memory
  • sexual problems in males
  • sleepiness
  • stomach pain, upset, or discomfort

For Healthcare Professionals

Applies to carbamazepine: compounding powder, intravenous solution, oral capsule extended release, oral suspension, oral tablet, oral tablet chewable, oral tablet extended release


Very common (10% or more): Nausea (29%), vomiting (18%), constipation (10%)
Very rare (less than 0.01%): Colitis, glossitis, stomatitis, pancreatitis
Frequency not reported: Dryness of the mouth, with suppositories occasional rectal irritation may occur, diarrhea, oral ulceration
Postmarketing reports: Gastric distress, abdominal pain, anorexia[Ref]

A single case of chemical pancreatitis has been reported in association with carbamazepine intoxication.[Ref]


Carbamazepine increases the rate of T4 and T3 metabolism and may lead to hypothyroidism in patients with hypothyroidism who are being treated with T4. Carbamazepine may also cause a 20% to 40% decrease in serum total and free T4 concentrations and a smaller decrease in serum total and free T3 concentrations in patients who have no thyroid disease.

Chronic administration of carbamazepine (the active ingredient contained in Equetro) may increase total cholesterol and HDL cholesterol levels. Carbamazepine may also transiently increase serum triglyceride and LDL cholesterol levels. One study has suggested that demeclocycline may be useful in prophylaxis of carbamazepine-induced hyponatremia.[Ref]

Very rare (less than 0.01%): Increase in prolactin (with or without symptoms such as gynecomastia or galactorrhea), impaired male fertility and/or abnormal spermatogenesis, abnormal thyroid function tests (e.g., decreased L-thyroxine [FT4, T4, T3] and increased TSH)
Frequency not reported: Hyponatremia, pancreatitis, lower serum testosterone, lower free androgen indexes, increased cerebrospinal fluid thyrotropin-releasing hormone levels[Ref]


Very common (10% or more): Leucopenia
Common (1% to 10%): Eosinophilia, thrombocytopenia, neutropenia
Rare (0.01% to 0.1%): Leukocytosis, lymphadenopathy, folic acid deficiency
Very rare (less than 0.01%): Agranulocytosis, aplastic anemia, pure red cell aplasia, megaloblastic anemia, acute intermittent porphyria, reticulocytosis, hemolytic anemia
Frequency not reported: Aplastic anemia, pancytopenia, bone marrow depression, leukopenia, thrombophlebitis, thromboembolism, adenopathy[Ref]

Thrombocytopenia is the most common hematologic effect of carbamazepine and may be either mild and transient or severe. Significant decreases in white blood cell counts may occur although the values may still be within the normal range. Often counts will return to baseline during continued therapy, and therefore, discontinuation of carbamazepine may not be necessary. Dose reductions may also result in normalization of white blood cell counts. Aplastic anemia has been reported (although many of the reported cases had confounding exposures to other medications). The manufacturer reports an incidence of 2 per 1,000,000 patients for aplastic anemia and 6 per 1,000,000 patients for agranulocytosis. Cases of reticulocytosis have been reported rarely in association with carbamazepine therapy as well. In addition, cases of hemolytic anemia and erythroid arrest have been reported.

Both humoral and nonimmune mechanisms have been implicated in the etiology of carbamazepine-induced bone marrow suppression.[Ref]


Rare (0.01% to 0.1%): Disturbances of cardiac conduction
Very rare (less than 0.01%): Bradycardia, arrhythmias, AV-block with syncope, collapse, congestive heart failure, hypertension or hypotension, aggravation of coronary artery disease, thrombophlebitis, thromboembolism[Ref]

Most of the cases of cardiovascular effects reported have occurred in patients receiving carbamazepine for trigeminal neuralgia. The reported effects included congestive heart failure, edema, hypotension, syncope and arrhythmias. In general, the doses were titrated quickly because of severe pain. Many of the doses were higher than those used to treat epilepsy. Many of the reported cardiovascular effects resolved after discontinuation of carbamazepine.

Increased sympathetic activity in the setting of seizure-induced hypoxia could predispose a patient to sudden unexpected death in epilepsy (SUDEP).[Ref]

Nervous system

Very common (10% or more): Dizziness (44%), somnolence (32%), ataxia (15%) Common (1% to 10%): Headache, tremor, vertigo
Uncommon (0.1% to 1%): Abnormal involuntary movements (tremor, asterixis, dystonia, tics)
Rare (less than 0.1%): Choreoathetotic disorders, orofacial dyskinesia, oculomotor disturbances, speech disorders (e.g., dysarthria or slurred speech), peripheral neuritis, paresthesia, paretic symptoms, neuroleptic malignant syndrome
Frequency not reported: Drowsiness, fatigue, fever and chills[Ref]

Rigidity and oculogyric crises have been reported. Euphoria has also been reported and has led to abuse of carbamazepine in some patients. Impairment of psychomotor function has been noted in association with use of the liquid suspension of carbamazepine. Additionally, impaired cognition, exacerbations of focal seizures and asterixis have been reported in association with carbamazepine treatment. One case of a lingual-facial-buccal extrapyramidal reaction has also been described.

One study has suggested that gradual withdrawal of carbamazepine over ten days results in significantly fewer generalized tonic-clonic seizures compared to rapid withdrawal over four days.

One study has suggested that the epoxide metabolite of carbamazepine may be responsible for the occasional occurrence of seizure exacerbations in patients receiving carbamazepine.[Ref]


Rare (0.01% to 0.1%): A delayed multi-organ hypersensitivity disorder (of serum sickness type) with fever, skin rashes, vasculitis, lymphadenopathy, disorders mimicking lymphoma, arthralgia, leucopenia, eosinophilia, hepato-splenomegaly and abnormal liver function tests, occurring in various combinations, other organs may also be affected (e.g., lungs, kidneys, pancreas, myocardium, colon)
Very rare (less than 0.01%): Aseptic meningitis (with myoclonus and peripheral eosinophilia), anaphylactic reaction, angioedema
Frequency not reported: Multiorgan hypersensitivity reactions occurring days, weeks, or months after initiating treatment[Ref]

Rash and pruritus often resolve after discontinuation of carbamazepine therapy. Both cases of lupus-like syndrome resolved after discontinuation of carbamazepine. Stevens-Johnson syndrome, erythema multiforme, and a mononucleosis-like syndrome have also been reported.[Ref]


Very common (10% or more): Elevated gamma-GT (due to hepatic enzyme induction) usually not clinically relevant
Common (1% to 10%): Elevated alkaline phosphatase
Uncommon (0.1% to 1%): Elevated transaminases
Rare (0.01% to 0.1%): Cholestatic and hepatocellular jaundice, hepatitis of cholestatic, parenchymal (hepatocellular), or mixed type
Very rare (less than 0.01%): Granulomatous hepatitis, hepatic failure
Frequency not reported: Liver function test abnormalities, variegate porphyria, porphyria cutanea tarda[Ref]

Alterations in liver function tests may progress to hepatotoxicity including cholangitis, granuloma formation, fever and hepatocellular necrosis. Discontinuation of carbamazepine often results in improvement in laboratory abnormalities and liver injury.[Ref]


Very rare (less than 0.01%): Interstitial nephritis, renal failure, renal dysfunction (including albuminuria, hematuria, oliguria, and elevated BUN/azotemia)[Ref]


Very rare (less than 0.01%): Pulmonary hypersensitivity (characterized by fever, dyspnea, pneumonitis or pneumonia), pulmonary embolism[Ref]


Very common (10% or more): Allergic skin reactions, urticaria
Common (1% to 10%): Pruritus, rash, paresthesia
Uncommon (0.1% to 1%): Exfoliative dermatitis, erythroderma
Rare (0.01% to 0.1%): Systemic lupus erythematosus-like syndrome
Very rare (less than 0.01%): Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), photosensitivity, erythema multiforme, erythema nodosum, alterations in skin pigmentation, purpura, acne, sweating, alopecia, hirsutism, unusual bruising, pruritic and erythematous rashes, diaphoresis, onychomycosis, dermatitis
Frequency not reported: Psoriasiform eruption[Ref]

Dangerous, sometimes fatal skin reactions (Stevens Johnson syndrome and toxic epidermal necrolysis), that can be caused by carbamazepine therapy are significantly more common in patients with the human leukocyte antigen (HLA) allele, HLA-B 1502. This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including South Asian Indians. Patients with ancestry from areas in which HLA-B 1502 is present should be screened for the HLA-B 1502 allele before starting treatment with carbamazepine. If these individuals test positive, carbamazepine should not be started unless the expected benefit clearly outweighs the increased risk of serious skin reactions. Patients who have been taking carbamazepine for more than a few months without developing skin reactions are at low risk of these events ever developing from carbamazepine. This is true for patients of any ethnicity or genotype, including patients who test positive for HLA-B 1502.[Ref]


Common (1% to 10%): Diplopia, accommodation disorders (blurred vision)
Very rare (less than 0.01%): Lens opacities, conjunctivitis
Postmarketing reports: Diplopia, oculomotor disturbances, nystagmus, photosensitivity, visual hallucinations, scattered punctate cortical lens opacities, overall impairment of the chromatic and achromatic systems, increased intraocular pressure[Ref]


Frequency not reported: Disorders mimicking lymphoma[Ref]


Frequency not reported: Antibody deficiency
Postmarketing reports: Aseptic meningitis (with myoclonus and peripheral eosinophilia)[Ref]


Common (1% to 10%): Abnormal thinking
Rare (0.01% to 0.1%): Hallucinations (visual or acoustic), depression, loss of appetite, restlessness, aggressive behavior, agitation, confusion, talkativeness
Very rare (less than 0.01%): Activation of psychosis, rebound mania following discontinuation of therapy[Ref]


Very rare (less than 0.01%): Sexual disturbances/impotence, abnormal spermatogenesis (with decreased sperm count and/or motility)
Frequency not reported: Urinary frequency, acute urinary retention, oliguria with elevated blood pressure, azotemia, albuminuria, glycosuria, elevated BUN, microscopic deposits in the urine[Ref]


Common (1% to 10%): Hyponatremia, fluid retention, edema, weight gain, reduced plasma osmolarity due to an antidiuretic hormone (ADH)-like effect (leading in rare cases to water intoxication accompanied by lethargy)
Very rare (less than 0.01%): Disturbances of bone metabolism (decrease in plasma calcium and 25-OH-cholecalciferol) leading to osteomalacia, elevated cholesterol (including HDL cholesterol), elevated triglycerides[Ref]


Rare (0.01% to 0.1%): Muscle weakness
Very rare (less than 0.01%): Arthralgia
Postmarketing reports: Leg cramps[Ref]


Very rare (less than 0.01%): Taste disturbances, tinnitus, hyperacusis, hypoacusis, changes in pitch perception[Ref]


1. Pellock JM "Carbamazepine side effects in children and adults." Epilepsia 28 (1987): s64-70

2. Hebert AA, Ralston JP "Cutaneous reactions to anticonvulsant medications." J Clin Psychiatry 62 (2001): 22-6

3. Soman M, Swenson C "A possible case of carbamazepine-induced pancreatitis." Drug Intell Clin Pharm 19 (1985): 925-7

4. Cerner Multum, Inc. "Australian Product Information." O 0

5. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

6. "Product Information. Tegretol (carbamazepine)." Basel Pharmaceuticals, Summit, NJ.

7. Tsao CY, Wright FS "Acute chemical pancreatitis associated with carbamazepine intoxication." Epilepsia 34 (1993): 174-6

8. Kalff R, Houtkooper MA, Meyer JW, et al "Carbamazepine and serum sodium levels." Epilepsia 24 (1984): 390-7

9. Tormey WP "Mechanisms of carbamazepine-induced antidiuresis." J Neurol Neurosurg Psychiatry 56 (1993): 567

10. Delzompo M, Bocchetta A, Loviselli A, Martino E, Post RM, Ketter TA "Thyroid function during carbamazepine." Biol Psychiatry 36 (1994): 135-6

11. Kuz GM, Manssourian A "Carbamazepine-induced hyponatremia: assessment of risk factors." Ann Pharmacother 39 (2005): 1943-6

12. Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994): 1199-200

13. Brewerton TD, Jackson CW "Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in 6 patients." J Clin Psychiatry 55 (1994): 249-51

14. Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F "Thyroid hormones in epileptic children receiving carbamazepine and valproic acid." Pediatr Neurol 25 (2001): 43-6

15. Gandelman MS "Review of carbamazepine-induced hyponatremia." Prog Neuropsychopharmacol Biol Psychiatry 18 (1994): 211-33

16. Kamiyama T, Iseki K, Kawazoe N, Takishita S, Fukiyama K "Carbamazepine-induced hyponatremia in a patient with partial central diabetes insipidus." Nephron 64 (1993): 142-5

17. Lofgren E, Tapanainen JS, Koivunen R, Pakarinen A, Isojarvi JI "Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy." Epilepsia 47 (2006): 1441-6

18. Marangell LB, George MS, Bissette G, Pazzaglia P, Huggins T, Post RM "Carbamazepine increases cerebrospinal fluid thyrotropin-releasing hormone levels in affectively ill patients." Arch Gen Psychiatry 51 (1994): 625-8

19. Isojarvi JI, Airaksinen KE, Repo M, Pakarinen AJ, Salmela P, Myllyla VV "Carbamazepine, serum thyroid hormones and myocardial function in epileptic patients." J Neurol Neurosurg Psychiatry 56 (1993): 710-2

20. Isojarvi JIT, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV "Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine." Epilepsia 35 (1994): 1217-20

21. Uhde TW, Post RM "Effects of carbamazepine on serum electrolytes: clinical and theoretical implications." J Clin Psychopharmacol 3 (1983): 103-6

22. Strandjord RE, AAnderud S, Myking OL, Johannessen SI "Influence of carbamazepine on serum thyroxine and triiodothyronine in patients with epilepsy." Acta Neurol Scand 63 (1981): 111-21

23. Hawson GA, Bain BJ, Whyte I "Agranulocytosis after administration of carbamazepine." Med J Aust Jan (1980): 82-3

24. Terao T "Reticulocyte increase and carbamazepine." Am J Psychiatry 150 (1993): 1271-2

25. Sobotka JL, Alexander B, Cook BL "A review of carbamazepine's hematologic reactions and monitoring recommendations." DICP 24 (1990): 1214-9

26. Tohen M, Castillo J, Cole JO, et al "Thrombocytopenia associated with carbamazepine: a case series." J Clin Psychiatry 52 (1991): 496-8

27. Stroink AR, Skillrud DM, Kiely JM, Sundt TM Jr "Carbamazepine-induced hemolytic anemia." Acta Haematol 72 (1984): 346-8

28. Ponte CD "Carbamazepine-induced thrombocytopenia, rash, and hepatic dysfunction." Drug Intell Clin Pharm 17 (1983): 642-4

29. Terao T "Transient thrombocytopenia while continuing carbamazepine." Am J Psychiatry 150 (1993): 1750-1

30. Rush JA, Beran RG "Leucopenia as an adverse reaction to carbamazepine therapy." Med J Aust 140 (1984): 426-8

31. Shoenfeld Y, Ben Baruch N, Livni E, et al "Carbamazepine (tegretol)-induced thrombocytopenia." Acta Haematol 68 (1982): 74

32. Medberry CA, Pappas AA, Ackerman BH "Carbamazepine and erythroid arrest." Drug Intell Clin Pharm 21 (1987): 439-41

33. Schweiger FJ, Kelton JG, Messner H, et al "Anticonvulsant-induced marrow suppression and immune thrombocytopenia." Acta Haematol 80 (1988): 54-8

34. Baciewicz G, Yerevanian BI "Thrombocytopenia associated with carbamazepine: case report and review." J Clin Psychiatry 45 (1984): 315-6

35. Kenneback G, Bergfeldt L, Vallin H, et al "Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of thecardiac conduction system." Am Heart J 121 (1991): 1421-9

36. Verma SP, Yunis N, Lekos A, Crausman RS "Carbamazepine-induced systemic lupus erythematosus presenting as cardiac tamponade." Chest 117 (2000): 597-8

37. Boesen F, Andersen EB, Jensen EK, Ladefoged SD "Cardiac conduction disturbances during carbamazepine therapy." Acta Neurol Scand 68 (1983): 49-52

38. Weig SG, Pollack P "Carbamazepine-induced heart block in a child with tuberous sclerosis and cardiac rhabdomyoma - implications for evaluation and follow-up." Ann Neurol 34 (1993): 617-9

39. Hennessy MJ, Tighe MG, Binnie CD, Nashef L "Sudden withdrawal of carbamazepine increases cardiac sympathetic activity in sleep." Neurology 57 (2001): 1650-4

40. Levander HG "Granulomatous hepatitis in a patient receiving carbamazepine." Acta Med Scand 208 (1980): 333-5

41. Steckler TL "Lithium- and carbamazepine-associated sinus node dysfunction: nine-year experience in a psychiatric hospital." J Clin Psychopharmacol 14 (1994): 336-9

42. Pulliainen V, Jokelainen M "Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients." Acta Neurol Scand 89 (1994): 81-6

43. Smith KR, Goulding PM, Wilderman D, Goldfader PR, Holtermanhommes P, Wei FF "Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study." Arch Neurol 51 (1994): 653-60

44. Wildin JD, Pleuvry BJ, Mawer GE "Impairment of psychomotor function at modest plasma concentrations of carbamazepine after administration of the liquid suspension to naive subjects." Br J Clin Pharmacol 35 (1993): 14-9

45. Malow BA, Blaxton TA, Stertz B, Theodore WH "Carbamazepine withdrawal - effects of taper rate on seizure frequency." Neurology 43 (1993): 2280-4

46. Neufeld MY "Exacerbation of focal seizures due to carbamazepine treatment in an adult patient." Clin Neuropharmacol 16 (1993): 359-61

47. So EL, Ruggles KH, Cascino GD, Ahmann PA, Weatherford KW "Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide." Ann Neurol 35 (1994): 743-6

48. Ambrosetto G, Riva R, Baruzzi A "Hyperammonemia in asterixis induced by carbamazepine: two case reports." Acta Neurol Scand 69 (1984): 186-9

49. Stuppaeck CH, Whitworth AB, Fleischhacker WW "Abuse potential of carbamazepine." J Nerv Ment Dis 181 (1993): 519-20

50. Joyce RP, Gunderson CH "Carbamazepine-induced orofacial dyskinesia." Neurology 30 (1980): 1333-4

51. Parha S, Garoufi A, Yiallouros P, Theodoridis C, Karpathios T "Carbamazepine hypersensitivity and rickettsiosis mimicking kawasaki disease." Eur J Pediatr 152 (1993): 1040-1

52. Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995): 1600-7

53. De Giorgio CM, Rabinowicz AL, Olivas RD "Carbamazepine-induced antinuclear antibodies and systemic lupus erythematosus-like syndrome." Epilepsia 32 (1991): 128-9

54. Richens A, Davidson DLW, Cartlidge NEF, Easter DJ "A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy." J Neurol Neurosurg Psychiatry 57 (1994): 682-7

55. Roberts DL, Marks R "Skin reactions to carbamazepine." Arch Dermatol 117 (1981): 273-5

56. Suzuki Y, Fukuda M, Tohyama M, Ishikawa M, Yasukawa M, Ishii E "Carbamazepine-induced drug-induced hypersensitivity syndrome in a 14-year-old Japanese boy." Epilepsia 49 (2008): 2118-21

57. Meisel S, North CQ "Carbamazepine-associated erythema multiforme with extreme eosinophilia." Clin Pharm 3 (1984): 15-9

58. Merino N, Duran JA, Jimenez MC, Ravella R "Multisystem hypersensitivity reaction to carbamazepine." Ann Pharmacother 28 (1994): 402-3

59. Fsadni C, Fsadni P, Piscopo T, Mallia Azzopardi C "Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms syndrome in a 35-year-old man with epilepsy." Clin Neuropharmacol 31 (2008): 295-8

60. Bateman DE "Carbamazepine induced systemic lupus erythematosus: case report." Br Med J 291 (1985): 632-3

61. Takahashi N, Aizawa H, Takata S, Matsumoto K, Koto H, Inoue H, Hara N "Acute interstitial pneumonitis induced by carbamazepine." Eur Respir J 6 (1993): 1409-11

62. Hopen G, Nesthus I, Laerum OD "Fatal carbamazepine-associated hepatitis." Acta Med Scand 210 (1981): 333-5

63. Sheridan WP, King RW, Gerstman M "Fever as an adverse reaction to carbamazepine." Aust N Z J Med 12 (1982): 520-2

64. Soffer EE, Taylor RJ, Bertram PD, et al "Carbamazepine-induced liver injury." South Med J 76 (1983): 681-3

65. Levy M, Goodman MW, Van Dyne BJ, Sumner HW "Granulomatous hepatitis secondary to carbamazepine." Ann Intern Med 95 (1981): 64-5

66. Larrey D, Hadengue A, Pessayre D, et al "Carbamazepine-induced acute cholangitis." Dig Dis Sci 32 (1987): 554-7

67. Laspina I, Secchi P, Grampa G, Uccellini D, Porazzi D "Acute cholangitis induced by carbamazepine." Epilepsia 35 (1994): 1029-31

68. Swinburn BA, Croxson MS, Miller MV, Crawford KB "Carbamazepine induced granulomatous hepatitis." N Z Med J Mar (1986): 167

69. Horowitz S, Patwardhan R, Marcus E "Hepatotoxic reactions associated with carbamazepine therapy." Epilepsia 29 (1988): 149-54

70. Jubert P, Almirall J, Casanovas A, Garcia M "Carbamazepine-induced acute renal failure." Nephron 66 (1994): 121

71. Hogg RJ, Sawyer M, Hecox K, Eigenbrodt E "Carbamazepine-induced acute tubulointerstitial nephritis." J Pediatr 98 (1981): 830-2

72. Hegbrant J, Kurkus J, Oqvist B "Carbamazepine-related acute renal failure." Neurology 43 (1993): 446-7

73. King GG, Barnes DJ, Hayes MJ "Carbamazepine-induced pneumonitis." Med J Aust 160 (1994): 126-7

74. Brenner S, Wolf R, Landau M, Politi Y "Psoriasiform eruption induced by anticonvulsants." Isr J Med Sci 30 (1994): 283-6

75. Mecarelli O, Rinalduzzi S, Accornero N "Changes in color vision after a single dose of vigabatrin or carbamazepine in healthy volunteers." Clin Neuropharmacol 24 (2001): 23-6

76. DiLernia V, Viglio A, Cattania M, Paulli M "Carbamazepine-induced, CD30(+), primary, cutaneous, anaplastic large-cell lymphoma." Arch Dermatol 137 (2001): 675-6

77. Hayman G, Bansal A "Antibody deficiency associated with carbamazepine." BMJ 325 (2002): 1213

78. Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH "Riluzole augmentation for treatment-resistant depression." Am J Psychiatry 161 (2004): 2132

Not all side effects for Equetro may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.